dc.date.accessioned2019-02-22T14:54:29Z
dc.date.available2019-02-22T14:54:29Z
dc.date.created2019-02-22T14:54:29Z
dc.date.issued2015
dc.identifierhttps://hdl.handle.net/20.500.12866/5647
dc.identifierhttps://doi.org/10.1089/aid.2014.0241
dc.description.abstractMany studies of HIV/AIDS aggregate data from multiple cohorts to improve power and generalizability. There are several analysis approaches to account for cross-cohort heterogeneity; we assessed how different approaches can impact results from an HIV/AIDS study investigating predictors of mortality. Using data from 13,658 HIV-infected patients starting antiretroviral therapy from seven Latin American and Caribbean cohorts, we illustrate the assumptions of seven readily implementable approaches to account for across cohort heterogeneity with Cox proportional hazards models, and we compare hazard ratio estimates across approaches. As a sensitivity analysis, we modify cohort membership to generate specific heterogeneity conditions. Hazard ratio estimates varied slightly between the seven analysis approaches, but differences were not clinically meaningful. Adjusted hazard ratio estimates for the association between AIDS at treatment initiation and death varied from 2.00 to 2.20 across approaches that accounted for heterogeneity; the adjusted hazard ratio was estimated as 1.73 in analyses that ignored across cohort heterogeneity. In sensitivity analyses with more extreme heterogeneity, we noted a slightly greater distinction between approaches. Despite substantial heterogeneity between cohorts, the impact of the specific approach to account for heterogeneity was minimal in our case study. Our results suggest that it is important to account for across cohort heterogeneity in analyses, but that the specific technique for addressing heterogeneity may be less important. Because of their flexibility in accounting for cohort heterogeneity, we prefer stratification or meta-analysis methods, but we encourage investigators to consider their specific study conditions and objectives.
dc.languageeng
dc.publisherMary Ann Liebert
dc.relationAIDS Research and Human Retroviruses
dc.relation1931-8405
dc.rightshttps://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
dc.rightsinfo:eu-repo/semantics/restrictedAccess
dc.subjectPeru
dc.subjectAdolescent
dc.subjectAdult
dc.subjectFemale
dc.subjectHIV Infections
dc.subjectHumans
dc.subjectMale
dc.subjectYoung Adult
dc.subjectCaribbean
dc.subjectLatin America
dc.subjectBrazil
dc.subjectCohort Studies
dc.subjectTreatment Outcome
dc.subjectepidemiology
dc.subjectCaribbean Region
dc.subjectArgentina
dc.subjectAnti-Retroviral Agents
dc.subjectmortality
dc.subjectMexico
dc.subjecthuman
dc.subjectadult
dc.subjectcomparative study
dc.subjectfemale
dc.subjectmale
dc.subjectyoung adult
dc.subjectArticle
dc.subjectcohort analysis
dc.subjectHuman immunodeficiency virus infection
dc.subjectpriority journal
dc.subjecttreatment outcome
dc.subjectmajor clinical study
dc.subjectadolescent
dc.subjectChile
dc.subjectSouth and Central America
dc.subjectprocedures
dc.subjectobservational study
dc.subjectEpidemiologic Methods
dc.subjectsensitivity analysis
dc.subjectcase study
dc.subjectHaiti
dc.subjectHonduras
dc.subjectantiretrovirus agent
dc.subjecthazard ratio
dc.subjectanti human immunodeficiency virus agent
dc.subjectproportional hazards model
dc.subjectnonnucleoside reverse transcriptase inhibitor
dc.subjectbiostatistics
dc.subjectBiostatistics
dc.subjectfixed effect approach
dc.subjectHuman immunodeficiency virus proteinase inhibitor
dc.subjectmeta analysis approach
dc.subjectnaive approach
dc.subjectrandom cohort approach
dc.subjectrandom effect approach
dc.subjectrobust marginal approach
dc.subjectstratified approach
dc.subjecttreatment effect approach
dc.titleA comparison of seven cox regression-based models to account for heterogeneity across multiple HIV treatment cohorts in Latin America and the Caribbean
dc.typeinfo:eu-repo/semantics/article


Este ítem pertenece a la siguiente institución